Janux Therapeutics, Inc. (JANX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Janux Therapeutics, Inc. reported revenue of $10.00M, down 5.6% from the prior year. The company ran a net loss, with a net margin of -1136.2%. It held $1.00B in total assets against $44.74M in total liabilities.
Key ratios (FY2025)
-1576.7%
Operating margin
-1136.2%
Net margin
-11.9%
Return on equity
-5.6%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $10.00M | $10.59M | $8.08M | $8.61M | $3.64M | $0 | — |
| Operating Income | -$157.67M | -$98.85M | -$72.98M | -$67.09M | -$32.93M | -$4.84M | — |
| Net Income | -$113.62M | -$68.99M | -$58.29M | -$63.06M | -$32.67M | -$6.78M | — |
| EPS (Diluted) | $-1.83 | $-1.28 | $-1.32 | $-1.52 | $-1.39 | — | — |
| Total Assets | $1.00B | $1.06B | $380.41M | $364.01M | $379.82M | $16.22M | — |
| Total Liabilities | $44.74M | $38.73M | $36.06M | $43.27M | $13.50M | $9.23M | — |
| Shareholders' Equity | $956.82M | $1.02B | $344.35M | $320.74M | $366.33M | -$14.64M | -$7.94M |
| Cash & Equivalents | $52.33M | $430.61M | $19.20M | $51.43M | $35.58M | $7.81M | — |
| Operating Cash Flow | -$82.23M | -$43.81M | -$50.58M | -$42.92M | -$16.98M | -$4.37M | — |
| Capital Expenditures | $1.04M | $359.0K | $1.85M | $6.45M | $1.48M | $0 | — |
| Shares Outstanding | 60.38M | 59.06M | 46.25M | 41.62M | 41.24M | 1.05M | — |